Form 4: Xenon Pharmaceuticals Executive Exercises Options and Sells Shares
SEC Form 4 Filing
EVP Robin Sherrington exercised stock options and sold shares of Xenon Pharmaceuticals on March 7, 2024.
Summary
- On March 7, 2024, Robin Sherrington, EVP of Strategy & Innovation at Xenon Pharmaceuticals, exercised stock options to acquire 8,641 common shares at a price of $9.85 per share.
- Sherrington then sold 7,137 common shares at weighted average prices of $46.15 and $46.30 per share.
- After these transactions, Sherrington directly owns 8,398 common shares of Xenon Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option exercises and share sales by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of shares outstanding.
- The filing ensures transparency for shareholders regarding insider trading activities.
Key Dates
| Date | Description |
|---|---|
| 10/01/2014 | 1-for-4.86 reverse stock split of the Issuer's outstanding shares |
| 03/06/2024 | Closing price of the Company's common shares for net settlement calculations |
| 03/07/2024 | Date of earliest transaction: exercise of stock options and sale of shares |
| 03/08/2024 | Date of signature of the Form 4 filing |
| 03/11/2024 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.